UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 16, 2015
GALENA BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|
| | | | |
Delaware | | 001-33958 | | 20-8099512 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number)
| | (I.R.S. Employer Identification No.) |
| | | | |
| | 2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583 (855) 855-4253
| | |
| | (Address of Principal Executive Offices) (Zip Code)
| | |
| | | | |
Registrant’s telephone number, including area code: (855) 855-4253
|
| | | | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 16, 2015, Galena Biopharma, Inc. (“Galena”) received a subpoena from the U.S. Attorney’s Office for the District of New Jersey. The subpoena requests the production of a broad range of documents pertaining to marketing and promotional practices related to the product ABSTRAL® (fentanyl) Sublingual Tablets. Galena intends to cooperate with the government’s investigation. Galena can make no assurances as to the time or resources that will need to be devoted to this inquiry or its final outcome, or the impact, if any, of this inquiry or any proceedings on Galena’s business, financial condition, results of operations and cash flows.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | | | | | |
| | | | | | | | |
| | | | GALENA BIOPHARMA, INC. |
| | | | |
Date: | | December 22, 2015 | | | | By: | | /s/ Mark W. Schwartz |
| | | | | | | | Mark W. Schwartz Ph.D. President and Chief Executive Officer |